Introduction
The clinical course of HIV-1 infection in humans is characterized by a gradual loss of CD4 T cells [1] and increasing T cell dysfunction [2, 3] , eventually resulting in the development of AIDS. Although viraemia is controlled during the asymptomatic phase, high level virus replication has been shown throughout infection [4, 5] . Due to persistent virus replication and the error-prone nature of HIV-1 reverse transcriptase [6, 7] , the mutation rate of the viral genome is extremely high. The continuous emer-gence of mutant HIV-1 variants will facilitate escape from the immune system, development of resistance to antiretroviral therapy, and selection for beneficial biological properties such as coreceptor use and replicative capacity. Consequently, there is an ongoing evolution and high diversity of the viral quasispecies throughout infection.
Many species exhibit an antiviral activity that blocks retroviral infection at an early step in the viral replication cycle [8] [9] [10] [11] [12] [13] . Recently, the tripartite interaction motif 5a (Trim5a) was identified as an inhibitory factor that protects human and non-human primates against retroviruses [14, 15] . Trim5 is a member of the tripartite motif family and encodes five known isoforms that all contain a RING, B-box 2 and coiled-coiled domain [16] . Trim5a is the only isoform known to restrict retroviral replication and contains an additional C-terminal B30.2 or SPRY domain. The B30.2 and the coiled-coiled domain are involved in recognition of the viral capsid and are essential for the restriction activity of the protein [17] [18] [19] [20] [21] [22] [23] [24] .
Species-specific variations in Trim5a of different primates account for the restriction pattern of particular retroviruses [25] [26] [27] [28] [29] [30] [31] . For example, HIV-1 replication is blocked efficiently by Trim5a of rhesus macaques and African green monkeys, whereas SIV mac is restricted only by Trim5a from African green monkey cells. Human Trim5a efficiently blocks N-tropic murine leukaemia virus and equine infectious anaemia virus, but is much less efficient in restricting HIV-1 replication. This indicates that HIV-1 has at least partially adapted to the human variant of this restriction factor. Although inhibition of HIV-1 replication by human Trim5a has been observed in vitro [14, [32] [33] [34] , it remains unclear whether Trim5a contributes to host control of HIV-1 replication during the natural course of infection.
Recently we and others have demonstrated that the viral determinant in Trim5a mediated inhibition is located in the cyclophilin A (CyPA) binding region of the HIV-1 capsid and that mutations in this region resulted in resistance to this restriction [17, [35] [36] [37] [38] [39] . Interestingly, we and others have demonstrated that CyPA, which specifically interacts with HIV-1 capsid [40] [41] [42] [43] [44] , is required for Trim5a mediated restriction of HIV-1 in Old World monkey cells [34, 39, [45] [46] [47] . In contrast, CyPA supports HIV-1 infection in human cells by protecting HIV-1 from antiviral factors such as Trim5a [34, 35, 46, [48] [49] [50] . Mutations in the CyPA binding region associated with CyPA independent replication also resulted in escape from inhibition by human Trim5a [35] [36] [37] 39] . Interestingly, naturally occurring HIV-1 variants with mutations in the CyPA binding region associated with escape from Trim5a have recently been described [35, 51] .
Here we studied whether Trim5a escape variants of HIV-1 emerge during the course of infection. In addition, we analysed whether the clinical course of infection differed between individuals who developed Trim5a escape variants and those who did not.
Methods

Study population
The study population consisted of Caucasian homosexual men enrolled in the Amsterdam cohort studies (ACS) on the natural history of HIV-1 infection between October 1984 and February 1988. Of 364 participants, we selected 161 individuals with documented AIDS diagnosis or follow-up of at least 7 years without an AIDS diagnosis, and from whom cryopreserved peripheral blood mononuclear cells (PBMC) late in infection were available. Of this group, 96 individuals were seropositive at the time of entry into the ACS, while 65 individuals seroconverted during follow-up. Previous epidemiological studies on the incidence of HIV-1 infection amongst homosexual participants of the ACS have shown that infection in seroprevalent men occurred on average 1.5 years before entry into the ACS [52, 53] , therefore seroconversion of the seroprevalent group was set at 1.5 years before entry. Individuals did not receive HAART during the study period (censor date 1 January 1996), and developed AIDS (n ¼ 136; definition 1987 or 1993) before the censor date or had an asymptomatic follow-up of at least 7 years. ACS participants were routinely tested for the presence of CXCR4-using variants (X4-variants). Characteristics of the study population are summarized in Table 1 .
Longitudinally obtained clonal HIV-1 variants from 30 ACS participants were analysed for mutations in the CyPA binding region of capsid. Of 131 ACS participants, screening for the H87Q mutation in capsid was performed on viruses isolated relatively late in the course of infection, from 1 year before AIDS diagnosis or later. In individuals who developed X4-variants, viruses were isolated at least 1 year after the first detection of X4-variants. From individuals who did not develop X4-variants and who did not reach an endpoint during follow-up, viruses were isolated at least 7 years after seroconversion.
The ACS has been conducted in accordance with the ethical principles set out in the declaration of Helsinki and written informed consent was obtained prior to data collection. The study was approved by the Amsterdam Medical Center institutional medical ethics committee.
DNA isolation and sequencing
Clonal HIV-1 variants or bulk isolates were obtained as described previously [54] . Total DNA was isolated from Seroconversion of the seroprevalent occurred on average 1.5 years before entry into the cohort studies.
HIV-1 infected cell cultures. The CyPA binding region of capsid was amplified by PCR using primer pair p24-5E (5 0 -CAGCAATCAGGTCAGCCAAAATTAC-3 0 ) and p24-3E (5 0 -GTTACTTGGCTCATTGCTTCAGCC A-3 0 ) in the primary reaction and primer pair p17-F (5 0 -TGCTAAACACAGTGGGGGGACATC-3 0 ) and p17-R (5 0 -CAGCCAAAACTCTTGCCTTATGG-3 0 ) in the nested reaction. PCR products were sequenced with the ABI prism BigDye Terminator kit V1.1 (Applied Biosystems) using primers p17-F and p17-R. Sequences were analysed on an ABI 3130XL Genetic Analyzer.
HIV-1 based lentiviral vector production and infection
The green fluorescent protein expressing HIV-1 based lentiviral vector was described previously [55] . The mutant lentiviral vector containing a glutamine at position 87 and a valine at position 91 of capsid was created by a site directed mutagenesis (Stratagene, La Jolla California, USA) of the packaging construct. Lentiviral vectors were produced as previously described [55] . To determine the infectious titer, 293T cells were plated at a density of 1 Â 10 4 cells per well, and were transduced with serial dilutions of the vector. Four days after inoculation, transduction efficiency was analysed by fluorescenceactivated cell sorter.
TE671-Luc-shRNA and TE671-TR5-shRNA cells, a kind gift of J. Luban and E. Sokolskaja [34] , were cultured in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum (Hyclone, Logan, Utah, USA), antibiotic/antimycotic (Life Technologies, Rockville, Maryland, USA). Cells were plated at a density of 1 Â 10 4 per well and were inoculated with different amounts of LVafter 24 h. Infected cells were quantified by fluorescence-activated cell sorter analysis 5-6 days after inoculation.
Statistical analysis
For statistical analysis we assumed that the presence of Trim5a escape mutations in virus variants isolated at a late stage in infection is indicative for the presence of Trim5a selection pressure during the preceding period of infection. Hence the presence of escape mutations was treated as baseline time-fixed covariate. Kaplan-Meier and Cox proportional hazard analysis were performed to study the relationship between development of Trim5a escape variants and disease progression. Endpoints that were used for analysis were AIDS according to the 1987 Centers for Disease Control and Prevention definition, CD4 T cell counts < 200 cells/ml blood, and first detection of X4-variants [56] . We performed this analysis in the total group (n ¼ 161), participants who did not develop detectable X4-variants (R5-only), and the group of X4-patients. To allow this analysis, we assumed that individuals who developed X4-variants are different from R5-only individuals already before the appearance of X4-variants and thus development of X4-variants during follow-up was treated as a baseline time-fixed covariate. Univariate and multivariate relative hazards were calculated at 2 years after seroconversion for CD4 T cells at 18-30 months after seroconversion, viral RNA load at 18-30 months after seroconversion, the CCR5 genotype and development of Trim5a escape variants. Bivariate relative hazards were calculated at seroconversion for CCR5 genotype and development Trim5a escape variants.
Fisher's exact test was used to analyse an association between the H87Q mutation in capsid and development of X4-variants, R136Q polymorphism in Trim5a, and other mutations at position 91 and 96 of the CyPA binding region of the viral capsid. Mann-Whitney U test was used to analyse statistical differences in CD4 T cell count and viral RNA load between patients who did or did not develop Trim5a escape variants. Paired samples t test was used to compare the ability of lentiviral vectors to infect TE671-Luc-shRNA and TE671-TR5-shRNA cells. All analyses were performed using SPSS (release 13.0, SPSS Inc., Chicago, Illinois, USA).
Results
HIV-1 variants with the H87Q mutation in the CyPA binding region develop during the course of HIV-1 infection and are resistant to Trim5a mediated inhibition First we analysed if HIV-1 variants with Trim5a escape mutations in the CyPA binding region of the capsid protein developed during the natural course of infection. Clonal HIV-1 variants isolated from PBMC collected at different time points during HIV-positive follow-up in the ACS from 30 individuals were analysed for mutations in the CyPA binding region of capsid. The H87Q substitution was the only change observed that has previously been associated with resistance to Trim5a [17, [35] [36] [37] [38] [39] . Mutant viruses appeared in the late phase of infection in seven of 30 HIV-1 infected individuals, and ultimately became the dominant virus population (data not shown). Table 2 shows the sequence analysis of the CyPA binding region in longitudinally obtained HIV-1 variants from two representative cohort participants. In participant ACH19510 HIV-1 variants with the H87Q mutation appeared as a minor population 92 months after seroconversion, which was 14 months after the first detection of CXCR4-using variants (X4variants) and 9 months before AIDS diagnosis ( Table 2) . Six months later, all virus variants had the H87Q mutation. In participant ACH19829, H87Q mutants were first detected 51 months after seroconversion which was 12 months before the emergence of X4-variants and 32 months before AIDS diagnosis ( Table 2 ). In this patient co-existing wild-type HIV-1 variants could be detected at all subsequent time points.
To verify that the H87Q mutation in the CyPA binding region was indeed associated with escape from Trim5a, the mutation was introduced into the HIV-1 based lentiviral vector. TE671 cells knocked down for Trim5 using shRNA (TE671-TR5-shRNA) and control cells (TE671-Luc-shRNA) (a kind gift of J. Luban and E. Sokolskaja [34] ) were infected with wild-type or mutant lentiviral vector. Knock-down of Trim5a significantly enhanced infection by the wild-type lentiviral vector (P ¼ 0.002), whereas the infectivity of the mutant lentiviral vector was the same as in control cells indicating that the H87Q mutation was indeed associated with resistance to Trim5a mediated inhibition ( Fig. 1) .
Development of Trim5a escape variants late in infection is preceded by a prolonged asymptomatic phase
To analyse whether the development of Trim5a escape variants correlated with the clinical course of infection, we screened an additional 131 participants of the ACS for the presence of viruses with the H87Q mutation. HIV-1 was isolated relatively late in infection (>1 year after development of X4-variants, 1 year before AIDS diagnosis or later, or after a follow-up of at least 7 years in individuals who lacked X4-variants or a clinical endpoint). Virus variants with the Trim5a escape mutation were observed in 22 individuals (13.7%). The prevalence of Trim5a escape mutations was not significantly different between individuals who did or did not develop X4-variants in the course of infection (18.7% versus 9.3% in X4-and R5-only patients, respectively; P ¼ 0.108). Furthermore, there was no significant difference in time of sampling between patient groups that did or did not harbour viruses with the H87Q mutation.
Next, we performed Kaplan-Meier and Cox Proportional Hazard analyses on groups of patients that did or did not develop Trim5a resistance mutations, using clinical AIDS as an endpoint (definition 1987). This analysis showed a significant delay in disease progression of the group that ultimately developed Trim5a escape variants [log rank, P ¼ 0.034; relative hazard (RH), 0.418; 95% confidence interval (CI), 0.182-0.959; P ¼ 0.040; Fig. 2a ). In agreement, a significant difference was observed in the viral RNA load at 18 months after seroconversion between individuals who did or did not develop viruses with the H87Q mutation (3.9 AE 0.8 versus 4.4 AE 0.7 log viral RNA/ml plasma respectively, P ¼ 0.017).
Next, we studied whether the association between Trim5a and the clinical course of infection was independent of the development of X4-variants in the course of infection. To this end, we performed Kaplan-Meier and Cox proportional hazard analyses with clinical AIDS as an endpoint for individuals who did or did not develop Trim5a escape variants separately for individuals who did or did not develop X4-variants in their course of infection. 
Consensus sequence of the CyPA binding region of HIV-1 capsid. Amino acids at position 86 to 93 are given. 95% CI, 0.090-0.949; P ¼ 0.041; Fig. 2a ). However, no difference in the clinical course was observed in R5-only patients that did or did not develop Trim5a escape variants late in infection (n ¼ 86) ( Fig. 2a ). Individuals who late in infection developed X4-variants and Trim5a escape variants had slower CD4 declines in the preceding asymptomatic phase of infection as compared to X4patients who did not develop Trim5a escape variants (log rank, P ¼ 0.059; RH, 0.493; 95% CI, 0.233-1.043, P ¼ 0.064; Fig. 2b ). Finally, a statistically significant delayed time to first X4-variant emergence was observed in individuals who developed Trim5a escape variants late in infection (log rank, P ¼ 0.031; RH, 0.481; 95% CI, 0.244-0.947; P ¼ 0.034; Fig. 2c ).
As evolution to X4-variants requires the accumulation of mutations and therefore active virus replication, the delayed emergence of X4-variants in individuals preceding Univariate and multivariate relative hazard analysis was used to determine the association between progression to AIDS and the development of Trim5a escape variants, the CCR5-genotype, CD4 T cell counts and plasma viral RNA load. Univariate analysis at 2 years after seroconversion indicated that all markers analysed here were predictive for a delayed disease progression (Table 3) . Multivariate analysis at 2 years after seroconversion implicated only viral RNA load < 10 4.5 copies/ml plasma as an independent predictor for delayed disease progression (Table 3) . At seroconversion, bivariate analysis revealed that the emergence of Trim5a escape variants ever in the course of infection was associated with prolonged AIDS free survival even after adjustment for CCR5-genotype (univariate: RH, 0.42; 95% CI, 0.18-0.97; P ¼ 0.42; bivariate: RH, 0.50; 95% CI, 0.26-0.94; P ¼ 0.030) ( Table 3 ).
Discussion
Human Trim5a is able to block HIV-1 replication albeit less efficiently than rhesus macaque Trim5a [14, 26, 27, 30, [32] [33] [34] . This suggests that the role of Trim5a in host control of virus burden during the asymptomatic phase of HIV-1 infection might be limited. Previous studies have demonstrated, however, that even a threefold decrease in viral RNA load in vivo significantly delayed disease progression for more than 2 years [57] . This indicates that even a limited inhibition of HIV-1 replication by Trim5a might influence HIV-1 pathogenesis.
Here we considered development of Trim5a escape mutations (H87Q) in HIV-1 indicative of Trim5a pressure on virus replication in vivo and screened HIV-1 isolates from homosexual participants of the ACS for this mutation. We observed that Trim5a escape variants developed late in the course of infection and only in a proportion of individuals. Interestingly, individuals who developed Trim5a escape variants late in infection experienced a significantly prolonged asymptomatic phase of infection as compared to individuals who did not develop Trim5a escape variants. Our data are compatible with a model in which Trim5a mediated inhibition of viral replication contributes to control of viral load in the early phase of infection, thereby prolonging the asymptomatic phase, while at the same time selecting for the emergence of Trim5a escape variants (Fig. 3) . Indeed, concomitant with Trim5a mediated control of wild-type virus replication early in infection, the viral load in individuals who developed Trim5a escape variants late in infection was significantly lower at 18 months after seroconversion as compared to individuals who did not develop Trim5a escape variants. In agreement with a relatively weak suppressive effect of human Trim5a on HIV replication, Trim5a resistant viruses developed relatively late in infection, before the onset of disease progression. One would predict that the emergence of Trim5a escape variants would precede a subsequent accelerated progression to AIDS. Lack of knowledge on the exact moment of H87Q variant development in the majority of our study population prevented us from analysing whether viral escape from Trim5a in vivo indeed results in an increase in viral RNA load and rapid disease progression (Fig. 3) .
The relatively small proportion of individuals that developed Trim5a resistant viruses may suggest that Trim5a mediated inhibition is significant in only a small group of the HIV-1 infected population. Trim5a activity in this group may be enhanced by polymorphisms in the Trim5a gene [32, [58] [59] [60] . The R136Q polymorphism has been associated with a slightly higher anti-HIV-1 activity of Trim5a [32] . This suggests that the 136Q variant of Trim5a might have a protective effect. Indeed, in one study it was reported that the SNP R136Q was more frequently observed in high risk seronegative as compared to HIV-1 infected individuals in African-Americans [32] . However, this could not be confirmed in other study populations [32, 59] . To determine whether the development of Trim5a escape variants was due to the higher antiviral activity associated with this polymorphism, we screened our study population for the R136Q mutation. However, no association between the R136Q polymorphism and the emergence of Trim5a escape variants was observed (data not shown).
Another explanation for the relatively low prevalence of HIV-1 with Trim5a escape mutations may be a fitness cost associated with this mutation. This seems likely as in the early asymptomatic phase of infection in all HIV-1 variants from our study subjects only wild-type CyPA binding regions of capsid were observed. The H87Q mutation might result in loss of fitness, which the virus can only afford in the late phase of infection. A preliminary comparison of in vitro replication kinetics in phytohaemagglutinin stimulated PBMC of wild-type and H87Q mutant viruses did not reveal significant differences (data not shown). It remains to be elucidated whether differences in viral fitness between wild-type and H87Q mutant viruses might be more definite in direct competition assays [61] .
Recently, it has been reported that mutations in the CyPA binding region were associated with CyPA independent infection in human cells [35, 36, 39, 51] . The H87Q mutation alone or in combination with V86P, A88P, I91Vand/or M96I rendered HIV-1 relatively insensitive to cyclosporine A or Debio-025 treatment, drugs that prevent the CyPA-capsid interaction. Chatterji et al. observed that substitutions at these positions were also present in naturally occurring HIV-1 variants [51] . Twenty-nine different sequences of the CyPA binding region were derived from the 24 subjects in our study that had HIV-1 variants with a mutation at position 87. A single mutation at position 87 was observed in five viruses (four H87Q; one H87P), whereas a mutation at position 87 in combination with additional mutations was observed in the other viruses (nine I91V; four I91V and M96I/L; two V86A/M; five V86A/Q/P and I91V; one V86A, I91V and M96I; two M96I; one V86M and M96I). In addition, we observed a significant association between mutations at position 86 (P ¼ 0.000003), 91 (P ¼ 0.0003) or 96 (P ¼ 0.011) and the mutation at position 87 in our study population. However, no independent significant effect of these mutations on disease progression as determined by Kaplan-Meier and Cox regression analysis was observed (data not shown).
Previously the H87Q mutation was observed in HIV-1 variants isolated from HLA-B57 positive individuals. In these individuals, escape mutations in the HLA-B57 restricted cytotoxic T lymphocyte epitope TW10 were observed and it was suggested that the H87Q was a compensatory mutation to restore replicative capacity of the otherwise attenuated phenotype of the TW10 escape mutant [62] . Our study population included 12 HLA-B57 positive individuals who all had HIV-1 variants with the T242N escape mutation in the TW10 epitope. However, virus variants from only seven individuals additionally contained the H87Q mutation. Moreover, the H87Q mutation was not exclusively observed in HLA-B57 individuals, which indicates that this mutation is not specifically compensating for attenuating escape mutations in HLA-B57 restricted CTL epitopes.
In conclusion, our study is the first to provide evidence for a potential effect of Trim5a mediated inhibition of viral replication in the clinical course of HIV-1 infection. The exact magnitude of this antiviral effect and the consequences of viral escape, both for viral fitness and the clinical course of infection, remain to be elucidated before therapeutic strategies based on enhancement of Trim5a activity or Trim5a derivatives may be pursued.
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